Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.02744 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Ishmael A Jaiyesimi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Corewell Health William Beaumont University Hospital, Royal Oak and Oakland University William Beaumont School of Medicine, Rochester, MI. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Staging. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 118 Literaturangaben.
Abstract (Originalsprache)
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline . PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer with driver alterations. METHODS This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized clinical trials (RCTs), with the latest time frame spanning February to October 2023. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened. The literature search included systematic reviews, meta-analyses, and randomized controlled trials. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Eight new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients based on targetable driver alterations. Additional information is available at www.asco.org/living-guidelines .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Corewell Health William Beaumont University Hospital, Royal Oak and Oakland University William Beaumont School of Medicine, Rochester, MI.
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- American Society of Clinical Oncology (ASCO), Alexandria, VA.
- St Luke's Mountain States Tumor Institute, Boise, ID.
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI.
ORCID-Profile: Natasha B Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish Gadgeel, Gregory Masters, Erin L Schenk, Lecia Sequist, Navneet Singh, Lyudmila Bazhenova, Janet Freeman-Daily, Naoki Furuya, Balazs Halmos, Ibrahim Hanna Azar, Jarushka Naidoo, Joshua E Reuss, David R Spigel, Dwight H Owen, Jyoti D Patel
Zitieren
APA
Jaiyesimi, I. A., Leighl, N. B., Ismaila, N., Alluri, K., Florez, N., Gadgeel, S., Masters, G., Schenk, E. L., Schneider, B. J., Sequist, L., Singh, N., Bazhenova, L., Blanchard, E., Freeman-Daily, J., Furuya, N., Halmos, B., Azar, I. H., Kuruvilla, S., Mullane, M., …, & Patel, J. D. (2024). Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02744
Vancouver
Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, et al. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.02744
BibTeX
@article{Jaiyesimi2024,
author = {Jaiyesimi, Ishmael A and Leighl, Natasha B and Ismaila, Nofisat and Alluri, Krishna and Florez, Narjust and Gadgeel, Shirish and Masters, Gregory and Schenk, Erin L and Schneider, Bryan J and Sequist, Lecia and Singh, Navneet and Bazhenova, Lyudmila and Blanchard, Elizabeth and Freeman-Daily, Janet and Furuya, Naoki and Halmos, Balazs and Azar, Ibrahim Hanna and Kuruvilla, Sara and Mullane, Michael and Naidoo, Jarushka and Reuss, Joshua E and Spigel, David R and Owen, Dwight H and Patel, Jyoti D},
title = {Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.02744}
}
EUVIMED